Xeris Biopharma Holdings, Inc. (XERS) posted $128 million in revenue for Q4 2025, marking a 22% year-over-year increase, driven by strong demand for its glucose management therapies. The company also highlighted progress in its next-generation insulin platform, reinforcing long-term growth prospects.
- Xeris Biopharma reported Q4 2025 revenue of $128 million, a 22% year-over-year increase.
- U.S. sales of Xeris’s ready-to-use insulin product rose 28% in Q4 2025.
- Phase 3 trial for inhaled insulin candidate XRS-502 is over 90% enrolled, with top-line data expected by mid-2026.
- Non-GAAP net loss narrowed to $18 million in Q4 2025 from $24 million in 2024.
- XERS shares rose 6.3% in after-hours trading following the earnings release.
- Full-year 2026 revenue guidance set at $510 million to $530 million, with cash flow breakeven targeted by year-end.
Xeris Biopharma reported fourth-quarter 2025 revenue of $128 million, up from $105 million in the same period the prior year, reflecting sustained commercial momentum. The increase was primarily fueled by a 28% rise in U.S. sales of its stable, ready-to-use insulin product, which continues to gain traction in diabetes management. The company also recorded a non-GAAP net loss of $18 million, narrowing from $24 million in Q4 2024, signaling improved operational efficiency. The company’s pipeline advancement remains a key focus, with Phase 3 trial data for its novel inhaled insulin candidate, XRS-502, expected by mid-2026. XERS announced that the trial has enrolled over 90% of its target patient population, with top-line results anticipated before the end of the first half of next year. The potential approval of XRS-502 could expand Xeris’s addressable market in the insulin delivery space and diversify its revenue base. Shares of XERS rose 6.3% in after-hours trading following the announcement, outpacing the broader healthcare sector, as measured by the Health Care Select Sector SPDR Fund (XLV), which gained 1.8% over the same period. Industry analysts noted that Xeris’s progress may influence investor positioning in biotech-focused ETFs, including the iShares Biotechnology ETF (IHI), which saw a 2.1% uptick in trading volume post-earnings. The results underscore growing confidence in specialty biopharmaceutical companies with near-term clinical catalysts. Xeris reiterated its full-year 2026 revenue guidance of $510 million to $530 million, reflecting continued confidence in commercial execution and pipeline momentum. Management emphasized that the company remains on track to achieve cash flow breakeven by the end of 2026, a critical milestone for its long-term sustainability.